Unknown

Dataset Information

0

Protective-antigen (PA) based anthrax vaccines confer protection against inhalation anthrax by precluding the establishment of a systemic infection.

ABSTRACT: An intense effort has been launched to develop improved anthrax vaccines that confer rapid, long lasting protection preferably with an extended stability profile amenable for stockpiling. Protective antigen (PA)-based vaccines are most favored as immune responses directed against PA are singularly protective, although the actual protective mechanism remains to be unraveled. Herein we show that contrary to the prevailing view, an efficacious PA-based vaccine confers protection against inhalation anthrax by preventing the establishment of a toxin-releasing systemic infection. Equally importantly, antibodies measured by the in vitro lethal toxin neutralization activity assay (TNA) that is considered as a reliable correlate of protection, especially for PA protein-based vaccines adjuvanted with aluminum salts appear to be not absolutely essential for this protective immune response.

SUBMITTER: Merkel TJ 

PROVIDER: S-EPMC3906346 | biostudies-literature | 2013 Sep

REPOSITORIES: biostudies-literature

Json Xml
altmetric image

Publications

Protective-antigen (PA) based anthrax vaccines confer protection against inhalation anthrax by precluding the establishment of a systemic infection.

Merkel Tod J TJ   Perera Pin-Yu PY   Lee Gloria M GM   Verma Anita A   Hiroi Toyoko T   Yokote Hiroyuki H   Waldmann Thomas A TA   Perera Liyanage P LP  

Human vaccines & immunotherapeutics 20130620 9

An intense effort has been launched to develop improved anthrax vaccines that confer rapid, long lasting protection preferably with an extended stability profile amenable for stockpiling. Protective antigen (PA)-based vaccines are most favored as immune responses directed against PA are singularly protective, although the actual protective mechanism remains to be unraveled. Herein we show that contrary to the prevailing view, an efficacious PA-based vaccine confers protection against inhalation  ...[more]

Similar Datasets

Unknown Lethal factor and anti-protective antigen IgG levels associated with inhalation anthrax, Minnesota, USA.
| S-EPMC3901492 | biostudies-literature
Unknown A three-dose intramuscular injection schedule of anthrax vaccine adsorbed generates sustained humoral and cellular immune responses to protective antigen and provides long-term protection against inhalation anthrax in rhesus macaques.
| S-EPMC3491539 | biostudies-literature
Unknown Recombinant vaccine displaying the loop-neutralizing determinant from protective antigen completely protects rabbits from experimental inhalation anthrax.
| S-EPMC3592347 | biostudies-literature
Unknown Select human anthrax protective antigen epitope-specific antibodies provide protection from lethal toxin challenge.
| S-EPMC2891133 | biostudies-literature
Unknown A CpG-Ficoll Nanoparticle Adjuvant for Anthrax Protective Antigen Enhances Immunogenicity and Provides Single-Immunization Protection against Inhaled Anthrax in Monkeys.
| S-EPMC4684989 | biostudies-literature
Unknown Th17-stimulating protein vaccines confer protection against Pseudomonas aeruginosa pneumonia.
| S-EPMC3443805 | biostudies-other
Unknown Membrane insertion by anthrax protective antigen in cultured cells.
| S-EPMC1156972 | biostudies-literature
Unknown Anthrax toxin component, Protective Antigen, protects insects from bacterial infections.
| S-EPMC7458312 | biostudies-literature
Unknown Inhibition of anthrax protective antigen outside and inside the cell.
| S-EPMC1797656 | biostudies-literature
Unknown Rabies virus glycoprotein as a carrier for anthrax protective antigen.
| S-EPMC1576297 | biostudies-literature